{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:04:50Z","timestamp":1780092290425,"version":"3.54.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.intimp.2017.09.005","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T21:45:49Z","timestamp":1507844749000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach"],"prefix":"10.1016","volume":"52","author":[{"given":"Antonio","family":"Pecoraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Crescenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francescopaolo","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2017.09.005_bb0005","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.iac.2015.07.006","article-title":"Immunoglobulin replacement therapy for primary immunodeficiency","volume":"35","author":"Sriaroon","year":"2015","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaip.2013.08.007","article-title":"Intramuscular versus intravenous immunoglobulin replacement therapy and measurement of immunoglobulin levels during immunoglobulin replacement therapy","volume":"1","author":"Lieberman","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.intimp.2017.09.005_bb0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.intimp.2017.09.005_bb0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2016.12.030","article-title":"Rapid infusions of human normal immunoglobulin 50g\/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia","volume":"44","author":"Spadaro","year":"2017","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2017.09.005_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0035","author":"WHO"},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.intimp.2017.01.025","article-title":"Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with eosinophilic granulomatosis with polyangiitis (EGPA)","volume":"45","author":"Pecoraro","year":"2017","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2017.09.005_bb0050","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2217\/imt.14.67","article-title":"An update on the use of immunoglobulin for the treatment of immunodeficiency disorders","volume":"6","author":"Albin","year":"2014","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.intimp.2017.09.005_bb0055","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J. Clin. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.09.005_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cei.12555","article-title":"Immunoglobulins: current understanding and future directions","volume":"178","author":"Jolles","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"Clinical picture and treatment of 2212 patients with common variable immunodeficiency","volume":"134","author":"Gathmann","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/asheducation.V2012.1.301.3798316","article-title":"The many faces of common variable immunodeficiency","volume":"2012","author":"Cunningham-Rundles","year":"2012","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International consensus document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2013.09.015","article-title":"The variable in common variable immunodeficiency: a disease of complex phenotypes","volume":"1","author":"Jolles","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0090","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"112(2)","key":"10.1016\/j.intimp.2017.09.005_bb0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"15","author":"Chapel","year":"2008","journal-title":"Blood"},{"issue":"119(7)","key":"10.1016\/j.intimp.2017.09.005_bb0105","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"16","author":"Resnick","year":"2012","journal-title":"Blood"},{"issue":"180","key":"10.1016\/j.intimp.2017.09.005_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2017.03.011","article-title":"Delay in diagnosis affects the clinical outcome in a cohort of cvid patients with marked reduction of iga serum levels","volume":"25","author":"Graziano","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0115","author":"ESID"},{"issue":"120(9)","key":"10.1016\/j.intimp.2017.09.005_bb0120","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2012-05-431064","article-title":"Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency","volume":"30","author":"Quinti","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2017.09.005_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(99)70246-5","article-title":"Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients","volume":"134","author":"Quartier","year":"1999","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005792-198505000-00001","article-title":"X-linked agammaglobulinemia: an analysis of 96 patients","volume":"64","author":"Lederman","year":"1985","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0135","first-page":"335","article-title":"High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia","volume":"146","author":"Liese","year":"1992","journal-title":"Am. J. Dis. Child."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2003.10.007","article-title":"Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency","volume":"110","author":"Quartier","year":"2004","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.md.0000100046.06009.b0","article-title":"The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients","volume":"82","author":"Winkelstein","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.intimp.2017.09.005_bb0155","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2013.085076","article-title":"Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.intimp.2017.09.005_bb0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaci.2013.02.028","article-title":"Controversies in IgG replacement therapy in patients with antibody deficiency diseases","volume":"131","author":"Gelfand","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0165","first-page":"32","article-title":"Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients","volume":"2","author":"Wolf","year":"2015","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2017.09.005_bb0170","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.iac.2015.07.003","article-title":"Specific antibody deficiencies","volume":"35","author":"Wall","year":"2015","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2017.09.005_bb0175","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0180","first-page":"71","article-title":"Natural history of specific antibody deficiency after IgG replacement therapy","volume":"82","author":"Ortigas","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/00365540600951192","article-title":"Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up","volume":"39","author":"Olinder-Nielsen","year":"1999","journal-title":"Scand. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0190","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaci.2011.01.061","article-title":"Association of anti-IgA antibodies with adverse reactions to \u03b3-globulin infusion","volume":"128","author":"Rachid","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol. Oncol."},{"issue":"6(224)","key":"10.1016\/j.intimp.2017.09.005_bb0205","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"19","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2017.09.005_bb0210","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.intimp.2017.09.005_bb0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.23.2810","article-title":"A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia","volume":"23","author":"Lachance","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0225","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","volume":"166\u2013167","author":"Spadaro","year":"2016","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2017.09.005_bb0235","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/1744666X.2014.902314","article-title":"Secondary antibody deficiency","volume":"10","author":"Duraisingham","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0240","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"3S","key":"10.1016\/j.intimp.2017.09.005_bb0245","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2017.09.005_bb0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11894-016-0491-3","article-title":"Gastrointestinal disorders associated with common variable immune deficiency (CVID) and chronic granulomatous disease (CGD)","volume":"18","author":"Uzzan","year":"2016","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1054\/blre.2001.0185","article-title":"Hematologic complications of primary immune deficiencies","volume":"16","author":"Cunningham-Rundles","year":"2002","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0260","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","article-title":"The EUROclass trial: defining subgroups in common variable immunodeficiency","volume":"111","author":"Wehr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2017.09.005_bb0265","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ebiom.2016.02.025","article-title":"Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency","volume":"6","author":"Ebbo","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2017.09.005_bb0270","first-page":"1","article-title":"General recommendations on immunization\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"National Center for Immunization and Respiratory Diseases","year":"2011","journal-title":"MMWR Recomm. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4161\/hv.2.1.2445","article-title":"Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults","volume":"2","author":"Dentinger","year":"2006","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.intimp.2017.09.005_bb0280","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2017.09.005_bb0285","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1081-1206(10)60572-8","article-title":"Assessment and clinical interpretation of polysaccharide antibody responses","volume":"99","author":"Paris","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaci.2012.04.028","article-title":"Vaccines in the assessment of patients for immune deficiency","volume":"130","author":"Ballow","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2017.09.005_bb0295","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2334-10-60","article-title":"The effect of age on the response to the pneumococcal polysaccharide vaccine","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2017.09.005_bb0300","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10875-012-9806-9","article-title":"Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used","volume":"33","author":"Balloch","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2017.09.005_bb0305","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CDLI.8.2.266-272.2001","article-title":"Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay","volume":"8","author":"Concepcion","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"9842","key":"10.1016\/j.intimp.2017.09.005_bb0310","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2017.09.005_bb0315","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.intimp.2017.09.005_bb0320","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0325","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jaci.2013.01.036","article-title":"Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement","volume":"131","author":"Agarwal","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2017.09.005_bb0330","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/jcp.2004.016204","article-title":"Primary antibody deficiency and diagnostic delay","volume":"58","author":"Seymour","year":"2005","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.intimp.2017.09.005_bb0335","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2500\/aap.2016.37.3987","article-title":"Intravenous and subcutaneous immunoglobulin G replacement therapy","volume":"37","author":"Bonilla","year":"2016","journal-title":"Allergy Asthma Proc."},{"issue":"3","key":"10.1016\/j.intimp.2017.09.005_bb0340","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) therapy\u2014practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.09.005_bb0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0394632016681577","article-title":"Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies","volume":"30","author":"Canessa","year":"2017","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2017.09.005_bb0350","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin. Exp. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917303442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917303442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:46:50Z","timestamp":1719514010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917303442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":70,"alternative-id":["S1567576917303442"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.09.005","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}